tetano
Editor, Senior Moderator
J Clin Med
. 2023 Jul 15;12(14):4700.
doi: 10.3390/jcm12144700. SARS-CoV-2 Related Myocarditis: What We Know So Far
Raffaella Mistrulli[SUP] 1 [/SUP], Armando Ferrera[SUP] 1 [/SUP], Melwyn Luis Muthukkattil[SUP] 1 [/SUP], Massimo Volpe[SUP] 1 2 [/SUP], Emanuele Barbato[SUP] 1 [/SUP], Allegra Battistoni[SUP] 1 [/SUP]
Affiliations
A minority of patients with severe acute respiratory syndrome coronavirus 2 (COVID-19) develop cardiovascular complications, such as acute cardiac lesions with elevated troponins, de novo systolic heart failure, pericardial effusion and, rarely, acute myocarditis. The prevalence of COVID-19-related myocarditis ranges from 10 to 105 cases per 100,000 COVID-19-infected individuals, with a male predominance (58%) and a median age of 50 years. The etiopathogenetic mechanism is currently unclear, but may involve direct virus-mediated damage or an exaggerated immune response to the virus. Mortality is high, as fulminant myocarditis (FM) develops very often in the form of cardiogenic shock and ventricular arrhythmias. Hence, medical therapy with ACE inhibitors and beta-blockers may not always be sufficient, in which case inotropic and immunosuppressive drugs, most commonly corticosteroids, may be necessary. In this review we analyze the current data on COVID-19 myocarditis, management strategies and therapy, with a brief description of COVID-19 vaccine-associated myocarditis to help clinicians dealing with this peculiar form of myocarditis.
Keywords: COVID-19; COVID-19 and myocarditis; COVID-19 related myocarditis; COVID-19–associated acute myocarditis; SARS-CoV-2; acute myocarditis; cardiovascular sequelae of COVID-19; post-acute sequelae of SARS-CoV-2.
. 2023 Jul 15;12(14):4700.
doi: 10.3390/jcm12144700. SARS-CoV-2 Related Myocarditis: What We Know So Far
Raffaella Mistrulli[SUP] 1 [/SUP], Armando Ferrera[SUP] 1 [/SUP], Melwyn Luis Muthukkattil[SUP] 1 [/SUP], Massimo Volpe[SUP] 1 2 [/SUP], Emanuele Barbato[SUP] 1 [/SUP], Allegra Battistoni[SUP] 1 [/SUP]
Affiliations
- PMID: 37510815
- PMCID: PMC10380706
- DOI: 10.3390/jcm12144700
A minority of patients with severe acute respiratory syndrome coronavirus 2 (COVID-19) develop cardiovascular complications, such as acute cardiac lesions with elevated troponins, de novo systolic heart failure, pericardial effusion and, rarely, acute myocarditis. The prevalence of COVID-19-related myocarditis ranges from 10 to 105 cases per 100,000 COVID-19-infected individuals, with a male predominance (58%) and a median age of 50 years. The etiopathogenetic mechanism is currently unclear, but may involve direct virus-mediated damage or an exaggerated immune response to the virus. Mortality is high, as fulminant myocarditis (FM) develops very often in the form of cardiogenic shock and ventricular arrhythmias. Hence, medical therapy with ACE inhibitors and beta-blockers may not always be sufficient, in which case inotropic and immunosuppressive drugs, most commonly corticosteroids, may be necessary. In this review we analyze the current data on COVID-19 myocarditis, management strategies and therapy, with a brief description of COVID-19 vaccine-associated myocarditis to help clinicians dealing with this peculiar form of myocarditis.
Keywords: COVID-19; COVID-19 and myocarditis; COVID-19 related myocarditis; COVID-19–associated acute myocarditis; SARS-CoV-2; acute myocarditis; cardiovascular sequelae of COVID-19; post-acute sequelae of SARS-CoV-2.